businesspress24.com - Horizon Pharma plc to Host Third Quarter 2014 Conference Call and Webcast on November 6, 2014
 

Horizon Pharma plc to Host Third Quarter 2014 Conference Call and Webcast on November 6, 2014

ID: 1311666

(firmenpresse) - DUBLIN, IRELAND -- (Marketwired) -- 10/21/14 -- Horizon Pharma plc (NASDAQ: HZNP) announced today that its third quarter 2014 financial results will be released on Thursday, November 6, 2014. Following the announcement, Horizon''s management will host a live conference call and webcast at 8:00 am Eastern Time to review the Company''s financial and operating results and provide a general business update.

The live webcast and a replay may be accessed by visiting Horizon''s website at . Please connect to the Company''s website at least 15 minutes prior to the live webcast to ensure adequate time for any software download that may be needed to access the webcast. Alternatively, please call 1-888-338-8373 (U.S.) or 973-872-3000 (international) to listen to the conference call. The conference ID number for the live call is 21893017. Telephone replay will be available approximately two hours after the call. To access the replay, please call 1-855-859-2056 (U.S.) or 404-537-3406 (international). The conference ID number for the replay is 21893017.

Horizon Pharma plc is a specialty biopharmaceutical company focused on improving patients'' lives by identifying, developing, acquiring and commercializing differentiated products that address unmet medical needs. The Company markets a portfolio of products in arthritis, inflammation and orphan diseases. Horizon''s U.S. marketed products are ACTIMMUNE® (interferon gamma-1b), DUEXIS® (ibuprofen/famotidine), RAYOS® (prednisone) delayed-release tablets and VIMOVO® (naproxen/esomeprazole). The Company expects to begin marketing PENNSAID® (diclofenac sodium topical solution) 2% w/w in the U.S. in January 2015. Horizon''s global headquarters are in Dublin, Ireland. For more information, please visit .



Elizabeth M. Higashi, CFA
Vice President, Investor Relations

+1 224-383-3285




Themen in dieser Pressemitteilung:


Unternehmensinformation / Kurzprofil:



Leseranfragen:



PresseKontakt / Agentur:



drucken  als PDF  an Freund senden  Clinical Ink Selected by Dell to Join Founders 50
Atossa Genetics Receives CE Mark for the ForeCYTE Breast Aspirator Device
Bereitgestellt von Benutzer: Marketwired
Datum: 21.10.2014 - 14:05 Uhr
Sprache: Deutsch
News-ID 1311666
Anzahl Zeichen: 0

contact information:
Contact person:
Town:

DUBLIN, IRELAND


Phone:

Kategorie:

Biotech


Anmerkungen:


Diese Pressemitteilung wurde bisher 91 mal aufgerufen.


Die Pressemitteilung mit dem Titel:
"Horizon Pharma plc to Host Third Quarter 2014 Conference Call and Webcast on November 6, 2014
"
steht unter der journalistisch-redaktionellen Verantwortung von

Horizon Pharma plc (Nachricht senden)

Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).


Alle Meldungen von Horizon Pharma plc



 

Who is online

All members: 10 565
Register today: 0
Register yesterday: 0
Members online: 0
Guests online: 71


Don't have an account yet? You can create one. As registered user you have some advantages like theme manager, comments configuration and post comments with your name.